| New International Coalition aims to expand global access to HIV/AIDS treatment |
|
Berlin/Dakar - A new international alliance - the
International HIV Treatment Access Coalition (ITAC) - launched today in Berlin and Dakar
aims to boost efforts to provide access to anti-retroviral drugs to the growing
number of people with HIV/AIDS in low and middle income countries who need
them. According to WHO/UNAIDS estimates presented in a new report being launched by
the Coalition today, millions of people living with HIV/AIDS in low and
middle-income countries face death within the coming years unless they can
access these life-saving medicines. Although they are not a cure, anti-retroviral drugs (ARVs) inhibit replication
of HIV, the virus that causes AIDS, and boost the immune system's ability to
fight infections. In all countries where ARVs have become widely available to
people living with HIV/AIDS since 1996, they have led to a dramatic reduction
of HIV-related illness and death. Ninety-five percent of the estimated 42 million people with HIV/AIDS live in
low and middle income countries, and these countries accounted for over 99% of
the 3.1 million AIDS deaths this year. WHO estimates that only about 300,000
people living with HIV/AIDS in these countries are currently using ARVs, that
represents only 5% of those who need them. Launching the Coalition, WHO Director-General Gro Harlem Brundtland said,
"Does anyone deserve to be sentenced to certain death because she or he
cannot access care that costs less that $2 a day? Is anyone's life worth so
little? Should any family become destitute as a result? Should children be
orphaned? The answers must be no, no, no and no." ITAC currently unites more than 50 partners including NGOs, donors and
governments, people living with HIV/AIDS and their advocates, the private
sector, academic and research institutions and international organizations
working to overcome the challenges of expanding ARV access. These include more
efficient sharing of information and technical data about what works in
successful programs, setting up reliable drug procurement systems, and training
health care workers. The group also aims to galvanize and coordinate donor
action and provide much-needed technical assistance to national HIV treatment
programs. It will be served by a small secretariat at WHO's Headquarters in Geneva. "These drugs have saved hundreds of thousands of lives in Europe and the United States,"
said International AIDS Society President Dr. Joep Lange. "They could do
the same for millions more in developing countries. If we can get cold Coca
Cola and beer to every remote corner of Africa,
it should not be impossible to do the same with drugs." There is a lot of action in different counties, by governments, donors, the
private sector, NGOs and other groups," said Stu Flavell, International
Coordinator of the Global Network of People Living with HIV/AIDS, a member of
the new coalition. "But we need these different players to pool their
knowledge and work together. That is the only way we are going to move from
treating 50 or 100 people in a village to treating hundreds of thousands across
the country." The Coalition has been created at a time of both crisis and opportunity. In the
worst affected countries, over a third of the adult population is now infected
with HIV. Although a number of people on ARV treatment increased by nearly two
thirds in sub-Saharan Africa in 2002, only 1%
of the 4.1 million people living with HIV/AIDS in the region who need treatment
now can get ARV medicines. But there is now a growing commitment to provide
access to ARV drugs through the public sector in Africa
and elsewhere. Botswana, Senegal, Nigeria,
Costa Rica, Cuba and Thailand have all recently set
ambitious treatment targets. Many governments have reduced import taxes and
duties on HIV-related drugs and commodities. "Extending access to life-saving anti-retroviral treatment is a moral,
political and economic imperative," said Dr. Peter Piot, Executive
Director of UNAIDS, the joint United Nations Programme on HIV/AIDS. "We
know it is technically feasible to save lives with these drugs, even in the
poorest settings. We now have to marshal the political will, the resources and
the infrastructure to make it a reality. |